JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - XERIS BIOPHARMA HOLDINGS INC
All right, good afternoon. Welcome to the Jefferies Healthier Conference in London. My name is Dennis Ding, biotech and spec pharma analyst here at Jefferies. I have the wonderful pleasure of having John Shannon and Josh Bennett here from Xeris. Welcome. Thank you. Thank you, Dennis. Maybe to level set everybody, just give us a bit of background around Xerise And we'll certainly talk about RecorLib, but just talk about all the progress you guys have made this year. Yeah, so Xeris is a fast-growing biopharma company. We just raised our guidance with our third quarter earnings to $395 to $405 million this year, so that's 37% growth at the midpoint. We've been carrying that type of growth. It's driven by three products, Recorlev, which I'm sure we're going to talk a lot about for Cushing's, G-Voke, which is basically an EpiPen for diabetics, for hypoglycemia, and then Caveas, which ist our ultra-rare product for primary periodic paralysis. Those three products with their growth trajectory, we also at the start of this quarter, we changed, we put our 2030 outlook, we raised that from just a year and a half ago, we set that at $750 million, we are now raised that to over a billion by 2030 with those three products, and then we have one more product in development, we're about to start the Phase 3 program there, which is 8121, which a once-weekly subcutaneous product for levothyroxine. I'll stop there, and I know you've got a lot of questions. Yeah, I mean, why don't we get started with RecorLiv? I mean the magnitude of growth has been really impressive, and I know you guys essentially doubled your sales force at the beginning of the year. So talk about how that has gone and talk about also demand and just where that's shaken out. Yeah, so RecorRiv is our growth engine for the company. We doubled our commercial footprint in January. so it's our third expansion since we launched this product in 2022 it was a very significant expansion for us as we look at this marketplace and the opportunity here there's tremendous growth in more and more people being screened and detected for hypercortisolism specifically in areas where there's resistant disease so resistant diabetes resistant hypertension resistance of obesity the drugs are on aren't working and therefore when you look and find cortisol levels you know two times above the upper limit of normal that's usually what what the clinicians are looking for you have you have if you found the culprit so there's a lot of movement in this space where more and more clinicians are testing for these patients recoralev is benefiting from that information in the marketplace there's data now that supports that guidelines have recently changed with ada and esad and and those are driving even more and more people to screen and detect and driving our growth adding our sales organization and expanding them really allows us to get to and scale with the the growth in this marketplace and and that really contributed to us really putting record love on a different growth trend um in the third quarter generally would take six to nine months we saw it come faster and a little more aggressive so that's why we've changed a lot of our led to a lot of changes of our longer-term trajectory was because of the record love being on a new growth trend that now we think will get us to a billion dollar product in in you know in three to four years sooner than we said before which was 20 35 so sure can you give a little bit more color as to the guideline updates and what what do guidelines say specifically and how are you guys capitalizing on that yeah specifically the guidelines talk about when you in the case of diabetes for example they say if you have resistant diabetes the insulin's not working then then you should test for cortisol levels and the guidelines basically all point to if you're 1.8 times above the upper limit of normal, then you should treat that cortisol level. Because what we find is when you bring the cortisol levels back to normal range, then the insulin works and other drugs work. So the guidelines are really important because it really helps the next level of primary care. Now the endocrinologists have been doing this for a couple of years now, but now this really opens up other categories, specifically primary care physicians who now have, not only the medical guidelines are clear here, but now they've got guidelines, you know, all the way down to ADA and ESAD. When you, when your sales reps are out in the field, are they seeing that broadening prescriber base beyond the specialists and into the PCPs? Yes, that's exactly what's, what's happening. So when we do our expansions, there's two things that happen. One is you find more patients within the existing prescribers, but you're finding more targets and that and that's really what's happening in this space for all three products in in this category everybody's finding more prescribers as more and more people are testing and screening for for cortisol levels okay can you comment a little bit about you know persistence and how long patients are on on record live and typically by the time they get record live have they failed other therapies or have they just been you know newly diagnosed you know let's start with the majority of the patients that are coming on record love more than 60 of them are new news never been on a medical therapy so there's not a lot of there's less and less switching in this space but most of them come in as new news so first time on therapy um and then in terms of persistence it's it's we we watch that trend line, but it's not going to change much with so many people new to therapy. The challenge with this space is these are very complex patients to treat, multiple comorbidities. And especially over the first three to four months, people will drop out because a couple of things. One is you get cortisol withdrawal. You feel good with cortisol and you pull that away and start getting in a normal range people feel that plus you're you're adjusting all their other meds their hypertensive agents their diabetes every everything you can imagine that they're on needs to be adjusted when cortisol levels get in normal so that there's a lot of you know if you get through the first three or four months people will be fine and for ever we have people that have been on recorla for 10 years so you just got to get through those first three to four months um in in this space and then and hanner but we watch our persistence we watch you know conversion rates all those things and we just you know keep the trend lines pretty flat when we're adding so many new patients um every month every week every quarter that those trend lines are going to hold pretty steady um and you know for some time sure okay um on third quarter earnings call you guys raised you know guidance uh not only uh pulling forward record of uh one billion uh by a couple of years but also a billion in total revenue in 2030 uh can you talk about you know why why now you know the timing of such uh what what have you seen that really gives you confidence to bridge where record lift is today which is around 225 250 to a billion yeah let's start with um first of all i was getting this question back in late summer wait your your numbers seem like you're going to hit that 750 so we knew we were going to have to adjust it but what we really were waiting to see one is is the where the new sales force expansion on record left kicking in and we saw that in the third quarter record did over 71 million um in the in the um in the third quarter and that puts us on a very different trajectory than we were in the first half of the year which we anticipated but it was a little better than even we expected so that trajectory first starts that then we add on to it our other two products are both in growth modes again gevo moved back into a growth mode so we think that's another you know a product that's going to grow indefinitely you know high single digit to maybe you know low double digit growth for years to come. And then Cavaeus, which would have been pretty flat and steady, we put that on a growth curve as well. And we've made some investments in the early start of the fourth quarter to even drive even more growth there and finding more patients. So with all three products growing and Recorlive on a new trajectory, we had to move our 2030 outlook up to more than a billion. Sure. So when I take a step back and look at all three projects in Cushing's today, they are all seeing a tremendous amount of growth. How should investors think about access, and at what point do you think payers will catch on and start putting in additional restrictions? Because we cover a lot of companies, and that has seemed to be a dynamic that occurs earlier than what other management teams have thought about. Yeah, we haven't seen it yet. Will we see it in the future? I don't know. I will tell you this category is all prior authorization, medical necessity. Every product has to go through that. So there's not a lot of opportunity to go and buy access with payers. You have to get each patient based on the medical need and medical necessity, and in those scenarios, payers, it's hard for them to play in that space. So we haven't seen it yet. I don't know that we'll see it. this is still rare disease i mean there's even when we look at the top end of the range maybe 40 50 000 patients out there so i'm not sure it's that big of a payer issue longer term we also know that there's significant improvement in multiple comorbidities in this space which again is what everybody's trying to do both at the clinician level and in many cases the payers okay um If you think about next year, right, can you help give us sort of bookends without it being guidance bookends in terms of, like, how we should think about Record Live growth, especially after the Salesforce expansion? Yes. Record Live is on a new trajectory. You can look at that and map that out. So it's pretty obvious what Recoralev will be able to do if you just look at the performance in the third quarter and what we've guided to for the rest of the year. So that's clear. Again, and we see all three products growing next year. So add in another 9%, 10% for GVOC, add in some growth for Cabeas, and that can give you some bookends. But all of them, you know, track towards us having a significant growth year next year, just like we did this year. Okay. So if we look at RecoraLib in Q3, that was around $70, $71 million. You annualize that, gets you at $280, and then you apply some level of continued growth in 27. So that kind of gets you to around a $350 million number, you now, using my back-of-the-elbow math. Do you think that's sort of a reasonable ballpark of what people should be expecting next year? Or better. Or better, okay. Perfect. Can we talk a little bit about GVOC? That product has been approved for a while. How are you seeing revenue growth over the next three to five years? Yeah, GVOG is an area where there's 15 million people today that, based on the medical guidelines, should have a ready-to-use glucagon just in case they go low. And we estimate that less than a million today have a GVOC ready or any kind of ready-To-Use glucagone out there. So there's lots of opportunity to not only educate about the guidelines, but also you really have to change practice with these clinicians because they've never had anything in the past. So it's a lot of effort to get them to adjust how they do and run their practice around their diabetes patients and making sure that if you're on these products, you have one of these just in case. Please make sure you pick it up. So that's an effort where we're starting to find more and more traction as we go here. And you can see that in the weekly prescriptions. The market's back to growing for the last couple quarters, and we're capturing more than our fair share of the market. When I think about the penetration of these glucagon products, they have been way lower than what you would expect. And I understand that changing physician behavior may take a little bit of time, but what efforts are you taking, maybe you and some of your competitors in the space, What efforts are you guys taking to really accelerate that? Because when I think about GVOC, maybe it's like a mid-to-high single-institute grow-up, but how do you accelerate that?" Yeah, that's a challenge because a typical endocrinologist or somebody, a diabetologist is a very busy person, and they're so focused on getting the insulin and getting the blood sugar in order that they, in many cases, forget to even mention that, oh, by the way, you should have one of these just in case. So putting it into their practice is the game for us, making sure it's flagged on their records, making sure its put into their guidelines and protocols within the office, and then reassuring to the patient, hey, don't forget to pick this up because they'll get there to the pharmacy, and if the physician didn't tell them, oh, by the way, you need to grab this, they'll be like, I didn't order that. Why do I need that, right? So all of that needs to be systematically changed, and that's a lot of what our team works on with the clinicians, with the offices, to help them, you know, kind of implement the standard that you have to change within the practice. Got it. And then what about Cabeas? How should we think about that? You know, you just talked about making some investments to return that back to growth. Like, what are some of those investments? I always, Cabeus is my favorite product. you know it's one of those products where what you do for the product in terms of patient support and things like that is as important even not sometimes even more important than the medicine itself so this is one of Those scenarios where we can continue to build we find the patients with caveas that's the first and foremost second we help we walk into a doctor's office and say you have someone like this this and this do you you might have a ppp patient do you know who that is and so we have to start with explaining what ppp is and then and then how do we treat that patient right and then supporting that along the way so we've we've made some incremental investments just in the last several weeks to put more field personnel out in the field to find these patients there's probably four to five thousand of them out there and there's you know plenty to go find. We feel like we've got good capabilities in terms of figuring out how to find them, and then get in there and get them on therapy. Perfect. Maybe in the last eight or nine minutes, we can shift over to your phase three program in hypothyroidism. So talk a little bit about the rationale there, and when do you think you can start the phase three? I'll let Josh go. Sure. So we've developed, as John said, a once-weekly therapy for patients with hypothyroidism and there are 22 million people treated on therapy today we're focused on a subset we're focus on we estimate to be three to five million patients who are unable to meet their treatment goals primarily because of issues absorbing the only thing they have available today which is oral therapy we're on the verge of starting our phase three right we'll initiate it by the end of the year and are very confident in our product's ability to meet this unmet need. We hear consistently from our physicians, KOLs, a very high level of enthusiasm for it. In fact, we were at the American Thyroid Association meeting just a couple years ago, a couple weeks ago, and were encouraged that multiple scientific sessions, KOL's, independent of our efforts, decided to highlight 8.1.21 as an excited development that they're eager to see come to market. Okay. And then you guys disclosed a pretty robust registrational package with multiple studies. So maybe give a little bit more info around that and, like, which study to really focus on, which one is really key to getting FDA approval. Yeah, absolutely. So we're very aligned with the agency on the study design, and KOLs are enthusiastic and practicing physicians are enthusiastic. And that's led to pillar one of our study design, which is a non-inferiority trial which will secure approval, and we expect to secure approval. And physicians have told us because they're familiar with the API, it gives them everything they need to start writing the drug. But because we also have to bolster our package to maximize the opportunity and to make sure we've got a robust data package for payers, There are two other kind of pillars to our program. One is that we will also initiate next year a special population study in patients who are poorly controlled on oral levothyroxine, convert them to XP81-21, and show that we can resolve persistent lack of control. The final piece is we're investing heavily in real-world evidence generation. This space has seen no innovation or minimal innovation for 40 years. There's not a lot of data, So we have an opportunity and an obligation to bring the unmet need to life. And at this same ATA meeting, we published for the first time some of these data. And what was really compelling to us is we've consistently believed that among the 22 million patients, 20% of them are appropriate candidates. What we found in our analysis is actually among the patients we looked at, 25% of the them were out of range twice in a one-year period. which is striking because most patients only get tested once a year, means in consecutive tests they were out of range. So we're seeing increasing data that the unmet need is very significant and persistent, and we have the opportunity pre-launch to really characterize that and bring it to life. And the phase three, I believe it's called cornerstone. That's right. That's the non-inferiority. Maybe talk about the design of that and why you guys selected non-interiority as the endpoint. Yeah, I think so. Cornerstone is a comparative non-inferiority trial versus the standard of care, which is oral levothyroxine, specifically Synthroid. We'll study 500 participants, randomize them one-to-one, and success is going to be the percentage of patients who have normal TSH at the end of the study, measured in the last two treatment periods, which are weeks 48 and 54. Why do we choose non- inferiority? I think it's based on the feedback from the FDA and the feedback from physicians said we need this and we want the highest probability path to approval. So Cornerstone gives us what we believe is a very high probability path of approval. But we didn't want to stop there, which is why also touchstone or special population study and our capstone pediatric study, as well as a ruled evidence are part of the total program. Got it. Okay. So then, like, I understand what you're saying about trying to maximize the probability of success. And I'm assuming that based off of your prior PK work and PKPD phase one, phase two study that you feel pretty confident that you should be within the range, that you shouldn't be non-inferior. But is there a scenario where you can actually achieve superiority? Yeah, I think that we are, if we achieve non-inferiority, we believe we can, with high confidence, we'll hit the 1 to 3 billion peak sales that we have set or possible with 8,121. And there's the opportunity to demonstrate superiority, both on the primary endpoint as well as some of our key secondary endpoints, which include measuring the proportion of time that patients are in range on key biochemical measures in the last six months of the study. And so we're not counting on that, but we do think we have the opportunity to do that, and that would only add to the data package, potentially add to the potential of the product. Okay. How are you thinking about access once you guys get approved on a non-inferiority, you know, phase three? Yeah, it's a great question because the KOL and physician enthusiasm is so high that it lets us really focus on access. And I think what it starts with is just to frame this. We're focused on the highest unmet need. And we hear this all the time. There are patients that just cannot get into range, and that leaves them with significant long-term morbidity. It's very well understood. It's Very Accepted. And the guidelines are clear. You have to get people into range. So given that, we built this integrated data package, but also we're focused just on these patients. So of the 3 to 5 million, we can achieve our goals with no more than 10% of that population. So by focusing on the highest unmet need, we believe the payers will be able to grant the access we need to power through. And most importantly, just like John was talking about for RecorLiv, every single patient will require prior authorization. They will require failure on oral. But they're already treated on oral today. And the failure is already in the chart. So we don't need to, we don' believe, initiate a new therapy. We just need to find the millions of patients that have demonstrated inability to achieve biochemical control and use that existing data for the prior authorization. And the payers, at the end of the day, this is a patient who's been demonstrated not to meet the guidelines where no other option will have demonstrated that they can help them get into range. But I guess help me understand, because the phase three, I believe, both the primary and also the secondaries, they are all being measured for non-inferiority, right? The secondaries will be measured for superiority and will allow for that. But it's the combination of the non- inferiority study to prove for well-controlled patients, as well as the real-world evidence and the special population study, in total, we believe, will ensure the access we need. Okay. When will you guys disclose the data? Yeah, so we're targeting top line by the end of 28. Okay. And do you have a sense on pricing so far? Yeah, I think that we're not – it's a little early, right? We're targeting approval in 2030, you know, four years away probably to guide on price. But I think when you look at what we've said, which is 1 to 3 billion peak sales, and needing only 10% of the population, I think can help understand maybe the bumpers in which we might fit. What I will say is we think our price assumptions are conservative and achievable. Perfect. Maybe in the last minute just remind us, you know, your cash, your debt, and then also maybe even BD, right? I know there's so many things happening and they're all going in the right direction, but what about all is good um you know we became profitable a little over a year ago we continue to stay profitable we continue to invest for more and more growth um including our existing products in our pipeline um and then then our next priority then becomes what do we do with the rest of the cash we're generating as we go forward because again we have 88 gross margins you know growing getting better each quarter. So we look down the BD line, and maybe, Josh, you can talk a little bit about some of the things you're looking at. Sure. I mean, BD is really the next frontier for us now that we have both the cash and the balance sheet capacity to be more aggressive. We're really focused on things that leverage our strengths, right? First and foremost, we have an incredible commercial engine, and the commercial engine is proven in ultra-rare, rare, and general endocrinology, so we think it's flexible enough to look at a lot of assets that may fit across rare and endocrinology. Ideally, we're targeting things that contribute revenue and growth in the next three to six years before 8.121 becomes very material to the P&L. But at the same time, we don't need to do BD. We would like to. So we're going to be disciplined and make sure that what we do is something we can execute on just as we always try to do is meet our expectations. Perfect. Well, I think that's all the time that we have today. thanks so much for being here thanks for having us
- Company
- XERIS BIOPHARMA HOLDINGS INC
- Keywords
- XERIS BIOPHARMA HOLDINGS INC